Experimental Hematology & Oncology
Scope & Guideline
Transforming Research into Breakthroughs in Hematology & Oncology
Introduction
Aims and Scopes
- Immunotherapy and Cellular Therapies:
The journal prominently features research on immunotherapeutic strategies, particularly CAR-T cell therapies and their applications in various blood cancers, reflecting a commitment to explore cutting-edge cellular therapies. - Molecular and Genetic Insights:
Emphasizing the role of genetic mutations and molecular pathways in cancer progression, the journal publishes studies that delve into the molecular underpinnings of hematological malignancies and their therapeutic implications. - Tumor Microenvironment and Metabolism:
Research on the tumor microenvironment, including interactions with immune cells and metabolic reprogramming, is a core focus area, highlighting the complexity of cancer biology and potential therapeutic targets. - Clinical Applications and Real-World Studies:
The journal prioritizes studies that translate laboratory findings into clinical practice, including multicenter trials and real-world outcomes of hematopoietic stem cell transplantation and novel therapeutic regimens. - Emerging Therapeutic Strategies:
It also explores novel therapeutic agents and combinations, including small molecules, bispecific antibodies, and targeted therapies, reflecting the journal's commitment to addressing evolving treatment landscapes.
Trending and Emerging
- Advancements in CAR-T Cell Therapy:
There is a significant trend towards exploring various aspects of CAR-T cell therapies, including novel constructs, combination therapies, and innovative delivery mechanisms, highlighting the potential for personalized cancer treatment. - Integrative Approaches to Tumor Microenvironment:
Increasing attention is being paid to the tumor microenvironment, with studies investigating how immune cells, stromal components, and metabolic factors influence tumor progression and therapy response. - Focus on Biomarkers and Precision Medicine:
Emerging themes include the identification of biomarkers for predicting treatment response and disease progression, emphasizing the shift towards precision medicine in hematological malignancies. - Role of Artificial Intelligence in Oncology:
Recent publications have begun to explore the application of AI and machine learning in diagnostics and treatment planning, indicating a growing interest in leveraging technology to enhance clinical outcomes. - Research on Novel Therapeutic Targets:
The journal is increasingly featuring studies on new therapeutic targets and pathways, particularly those involved in immune evasion and resistance mechanisms, reflecting a proactive approach to developing next-generation therapies.
Declining or Waning
- Traditional Chemotherapy Approaches:
Research focusing on standard chemotherapy regimens is becoming less frequent, as newer targeted therapies and immunotherapies gain traction and demonstrate improved efficacy and safety profiles. - Less Emphasis on Single-Agent Therapies:
There is a noticeable decline in studies centered on single-agent therapies, as combination therapies and multi-targeted approaches are increasingly recognized for their potential to overcome resistance. - Limited Exploration of Older Drug Classes:
The exploration of older drug classes and their mechanisms is waning, as the focus shifts towards innovative compounds and novel mechanisms of action that promise better clinical outcomes. - Decreased Interest in Basic Laboratory Models:
Research utilizing basic laboratory models without translational implications appears to be declining, as the journal emphasizes studies that bridge laboratory findings to clinical relevance. - Reduction in Studies on Rare Hematological Disorders:
There seems to be a decrease in the volume of research dedicated to rare hematological disorders, likely due to the concentration on more prevalent and impactful malignancies.
Similar Journals
EXPERIMENTAL HEMATOLOGY
Exploring Innovations in Hematology and BeyondEXPERIMENTAL HEMATOLOGY, published by Elsevier Science Inc, is a leading journal in the field of hematology, distinguished by its impactful contributions to the study of blood-related disorders and cellular biology. With an ISSN of 0301-472X and an E-ISSN of 1873-2399, this journal has established a significant presence since its inception in 1973, continuing to be relevant through 2024. It holds a commendable Q1 ranking in Hematology and Q2 in various significant categories including Cancer Research, Cell Biology, Genetics, and Molecular Biology, recognizing its quality and influence in the scientific community. Researchers and professionals can access a wide range of meticulously peer-reviewed articles that promote cutting-edge research and foster collaboration across disciplines. As a vital platform for disseminating innovative findings, EXPERIMENTAL HEMATOLOGY empowers its audience to delve deeper into the complexities of hematological research and brings to light the advances critical for improving patient outcomes.
Turkish Journal of Hematology
Connecting researchers and clinicians to elevate hematology practices.Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.
AMERICAN JOURNAL OF HEMATOLOGY
Advancing Hematological Science Through Rigorous ResearchAmerican Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.
HEMATOLOGICAL ONCOLOGY
Exploring Breakthroughs in Cancer and Blood DisordersHEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.
Blood Science
Advancing Hematology Through Innovative ResearchBlood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.
Journal of Hematology & Oncology
Catalyzing Breakthroughs in Blood Health and Cancer CareJournal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.
Hematology-American Society of Hematology Education Program
Transforming Hematology through Comprehensive LearningHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
Molecular Therapy Oncolytics
Unleashing the Potential of Molecular Therapies for CancerMolecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.
Journal of Hematology
Bridging Knowledge Gaps in HematologyThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Driving excellence in cancer and hematology research.CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.